Blood Clot Prevention Study in Myeloma Patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a new diagnosis of multiple myeloma that is causing symptoms or other problems.
- You must be about to start your very first treatment for myeloma.
- You must not have had a blood clot in the 6 months before your myeloma diagnosis.
- You cannot already be taking a combination of blood thinners and antiplatelet drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
This study looks at bleeding in people who have just been diagnosed with multiple myeloma. If you join, you will answer questionnaires so the researchers can understand who is more likely to bleed while taking blood-thinning medication.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.